
Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
Publication
, Journal Article
McCreary, EK; Davis, MR; Narayanan, N; Andes, DR; Cattaneo, D; Christian, R; Lewis, RE; Watt, KM; Wiederhold, NP; Johnson, MD
Published in: Pharmacotherapy
October 2023
Triazole antifungals (i.e., fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) are commonly used in clinical practice to prevent or treat invasive fungal infections. Most triazole antifungals require therapeutic drug monitoring (TDM) due to highly variable pharmacokinetics, known drug interactions, and established relationships between exposure and response. On behalf of the Society of Infectious Diseases Pharmacists (SIDP), this insight describes the pharmacokinetic principles and pharmacodynamic targets of commonly used triazole antifungals and provides the rationale for utility of TDM within each agent.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Pharmacotherapy
DOI
EISSN
1875-9114
Publication Date
October 2023
Volume
43
Issue
10
Start / End Page
1043 / 1050
Location
United States
Related Subject Headings
- Voriconazole
- Triazoles
- Pharmacology & Pharmacy
- Pharmacists
- Mycoses
- Humans
- Drug Monitoring
- Communicable Diseases
- Antifungal Agents
- 3214 Pharmacology and pharmaceutical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McCreary, E. K., Davis, M. R., Narayanan, N., Andes, D. R., Cattaneo, D., Christian, R., … Johnson, M. D. (2023). Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy, 43(10), 1043–1050. https://doi.org/10.1002/phar.2850
McCreary, Erin K., Matthew R. Davis, Navaneeth Narayanan, David R. Andes, Dario Cattaneo, Robbie Christian, Russell E. Lewis, Kevin M. Watt, Nathan P. Wiederhold, and Melissa D. Johnson. “Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.” Pharmacotherapy 43, no. 10 (October 2023): 1043–50. https://doi.org/10.1002/phar.2850.
McCreary EK, Davis MR, Narayanan N, Andes DR, Cattaneo D, Christian R, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy. 2023 Oct;43(10):1043–50.
McCreary, Erin K., et al. “Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.” Pharmacotherapy, vol. 43, no. 10, Oct. 2023, pp. 1043–50. Pubmed, doi:10.1002/phar.2850.
McCreary EK, Davis MR, Narayanan N, Andes DR, Cattaneo D, Christian R, Lewis RE, Watt KM, Wiederhold NP, Johnson MD. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy. 2023 Oct;43(10):1043–1050.

Published In
Pharmacotherapy
DOI
EISSN
1875-9114
Publication Date
October 2023
Volume
43
Issue
10
Start / End Page
1043 / 1050
Location
United States
Related Subject Headings
- Voriconazole
- Triazoles
- Pharmacology & Pharmacy
- Pharmacists
- Mycoses
- Humans
- Drug Monitoring
- Communicable Diseases
- Antifungal Agents
- 3214 Pharmacology and pharmaceutical sciences